Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:40 2024-05-24 am EDT			5-day change	1st Jan Change
29 ^SEK	-3.33%		-21.20%	-18.99%

May. 08	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	CI

Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 02:30 am EDT

Guard Therapeutics International AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was SEK 14.51 million compared to SEK 39.92 million a year ago.

Latest news about Guard Therapeutics International AB

Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	Apr. 15	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	Jan. 31	CI
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	Jan. 15	MT
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	Jan. 15	CI
Guard Therapeutics International AB Appoints Nomination Committee for 2024	Dec. 07	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	23-09-28	CI
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	23-09-19	CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA	23-07-14	CI
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation	23-06-14	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Guard Therapeutics Provides Updated Information on the Phase 2 Study AKITA	23-05-02	CI
Guard Therapeutics Plummets 87% Amid Termination of Mid-stage Trial for Kidney Failure Drug	23-04-14	MT
Guard Therapeutics International AB Presents Positive Clinical Data with RMC-035 in Patients Undergoing Kidney Transplantation	23-03-16	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA	23-02-16	CI
Guard Therapeutics International AB Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial	23-02-10	CI
Guard Therapeutics International AB Announces Nomination Committee Appointments	22-12-20	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Guard Therapeutics International AB Receives FDA Fast Track Designation for RMC-035	22-11-08	CI
Guard Therapeutics International AB Receives IND Approval from the FDA for RMC-035	22-10-10	CI

Chart Guard Therapeutics International AB

Duration

Period

Chart Guard Therapeutics International AB

More charts

Company Profile

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GUARD THERAPEUTICS INTERNATIONAL AB	-18.99%	27.41M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research